Has the time come for a systematic top-down approach in Crohn's disease?

Competing Interests: MF has received consulting or lecture fees from AbbVie, Amgen, Arena, Biogen, Celltrion, CTMA, Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts, MSD, Gilead, Fresenius, Celgene, Sandoz, and Ferring. AB has received consulting fees from AbbVie, Amgen, Arena, Biogen, Celltrion, CTMA, Fresenius-Kabi, Galapagos, Janssen, MSD, Nexbiome, Pfizer, Roche, Takeda, and Tillott; lecture fees from AbbVie, Amgen, Biogen, Fresenius-Kabi, Galapagos, Janssen, Mayoli-Spindler, MSD, Norgine, Pfizer, Roche, Takeda, Tillotts, and Vifor Pharma; and research grants from AbbVie, Celltrion, Janssen, Lilly, Pfizer, and Takeda.